The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
View original at finance.yahoo.comThe Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson For Immediate Releases Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Intuitive Surgical has an expected revenue and earnings growth rate of 14.3% and 11.1%, respectively, for the current year
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidenceEli Lilly has a Zacks Rank #1 (Strong Buy)
80% confidenceREGN has an ROE of 13.8% compared with the industry's ROE of -65.41% and the S&P 500's ROE of 17%
80% confidenceRegeneron Pharmaceuticals has an expected revenue and earnings growth rate of 4.9% and -0.4%, respectively, for the current year
80% confidenceJohnson & Johnson has an expected revenue growth rate of 5% for the current year
80% confidenceThe healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers
80% confidenceEli Lilly currently sports a Zacks Rank #1 (Strong Buy)
80% confidenceHypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity
80% confidenceRegeneron carries a Zacks Rank #2
80% confidenceEli Lilly has a return on equity of 109.5% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceISRG has an ROE of 15.1% compared with the industry's ROE of -18.7% and the S&P 500's ROE of 17%
80% confidenceRegeneron Pharmaceuticals has an expected revenue growth rate of 4.9% for the current year
80% confidenceEli Lilly has an expected revenue growth rate of 22.3% for the current year
80% confidenceIntuitive Surgical has an expected revenue growth rate of 14.3% for the current year
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceRegeneron Pharmaceuticals carries a Zacks Rank #2 (Buy)
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceZacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to S&P 500's +7.7% average gain per year
80% confidenceThe supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.
80% confidenceMDT has an ROE of 14.9% compared with the industry's ROE of -2.5% and the S&P 500's ROE of 17%
80% confidenceThe medical sector is one of the major adopters of artificial intelligence, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster as well as more accurate diagnosis
80% confidenceMedtronic has an expected earnings growth rate of 2.7% for the current year (ending April 2026)
80% confidenceJohnson & Johnson has an expected earnings growth rate of 5.7% for the current year
80% confidenceMedtronic has an expected revenue growth rate of 7.5% for the current year (ending April 2026)
80% confidenceJNJ has an ROE of 32.7% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceRegeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidenceIntuitive Surgical carries a Zacks Rank #2 (Buy)
80% confidenceJohnson & Johnson has an expected revenue and earnings growth rate of 5% and 5.7%, respectively, for the current year
80% confidence